CONCORDBIOPharmaceuticals
Concord Biotech Ltd — PE Ratio & Valuation Analysis
₹1018.40
-2.34%
Current P/E46.19xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E59.0x21.8% below avg
⚠️
45.4% Premium to Industry
CONCORDBIO P/E 46.19x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹35.52 | ₹1346 | 37.9x |
| 2024 | ₹29.45 | ₹2211 | 75.1x |
| 2023 | ₹22.95 | ₹1472 | 64.1x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Concord Biotech Ltd Valuation
Concord Biotech Ltd (CONCORDBIO) currently trades at 46.19x earnings. The Pharmaceuticals sector average PE is 31.77x. CONCORDBIO commands a premium, reflecting high growth expectations. Historically, CONCORDBIO has traded at an average PE of 59.0x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
21.27%
Dividend Yield
0.75%
More on Concord Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.